GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Forward PE Ratio

ADCT (ADC Therapeutics) Forward PE Ratio : 0.00 (As of Jul. 01, 2025)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Forward PE Ratio?

ADC Therapeutics's Forward PE Ratio for today is 0.00.

ADC Therapeutics's PE Ratio without NRI for today is 0.00.

ADC Therapeutics's PE Ratio (TTM) for today is 0.00.


ADC Therapeutics Forward PE Ratio Historical Data

The historical data trend for ADC Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Forward PE Ratio Chart

ADC Therapeutics Annual Data
Trend
Forward PE Ratio

ADC Therapeutics Quarterly Data
Forward PE Ratio

Competitive Comparison of ADC Therapeutics's Forward PE Ratio

For the Biotechnology subindustry, ADC Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADC Therapeutics's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADC Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where ADC Therapeutics's Forward PE Ratio falls into.


;
;

ADC Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


ADC Therapeutics  (NYSE:ADCT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


ADC Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ADC Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).